VIVUS (VVUS) Submits Amdendment to REMS for Qsymia to Expand Distribution
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) announced that it has submitted an amendment to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia. The proposed REMS modification would allow dispensing through a broader range of certified pharmacies, specifically select retail pharmacies, to increase access while meeting all requirements of the REMS. The REMS modification was made at the mutual request of VIVUS and the FDA.
Within the current REMS program, Qsymia is available through certified mail order pharmacies that are part of the Qsymia Home Delivery Network, including CVS Pharmacy, Express Scripts and Walgreens. The REMS program includes a Medication Guide, healthcare provider training, patient brochure and other education tools. These same tools also will be available as part of the proposed modified REMS program.
“Our REMS has been, and will continue to be, a key element in the Qsymia launch and we look forward to working with the FDA on the modification request,” said Dr. Barbara Troupin, Vice President of Scientific Communication & Risk Management at VIVUS.
Qsymia is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). It is the first FDA-approved once daily combination therapy for the treatment of obesity.
Within the current REMS program, Qsymia is available through certified mail order pharmacies that are part of the Qsymia Home Delivery Network, including CVS Pharmacy, Express Scripts and Walgreens. The REMS program includes a Medication Guide, healthcare provider training, patient brochure and other education tools. These same tools also will be available as part of the proposed modified REMS program.
“Our REMS has been, and will continue to be, a key element in the Qsymia launch and we look forward to working with the FDA on the modification request,” said Dr. Barbara Troupin, Vice President of Scientific Communication & Risk Management at VIVUS.
Qsymia is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). It is the first FDA-approved once daily combination therapy for the treatment of obesity.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Space-Eyes names four directors ahead of planned Nasdaq listing
- RenX Enterprises agrees to sell Georgia property for $2.6M
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
